Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry

Lokesh Jain, Erin R. Gardner, Jürgen Venitz, Giuseppe Giaccone, Brett E. Houk, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


A simple, rapid and sensitive liquid chromatography/tandem mass spectrometric (LC/MS/MS) analytical method was developed for quantification of Hsp90 inhibitor PF-04928473 in human plasma, following administration of its prodrug, PF-04929113. Sample processing involved protein precipitation by addition of 0.4mL of methanol containing internal standard (PF-04972487) to 50μL volume of plasma sample. Chromatographic separation of PF-04928473 and PF-04972487 was achieved on a Phenomenex ® Luna C18(2) (2.0mm×50mm, 5μm) column using a gradient elution method with mobile phase solvents: methanol containing 0.1% formic acid and 0.1% formic acid at a flow rate of 0.25mL/min. Detection was performed in electrospray positive ionization mode, monitoring the ion transitions from m/z 465.1→350.1 (PF-04928473) and m/z 447.0→329.1 (PF-04972487). The retention times for PF-04928473 and PF-04972487 were 1.86 and 2.85min, respectively. Calibration curves were generated in the range of 2-2000ng/mL. The accuracy and precision ranged from 94.1 to 99.0% and 86.7 to 97.6%, respectively, which were calculated using quality control samples of three different concentrations analyzed in quintuplicate on four different days.

Original languageEnglish
Pages (from-to)3187-3192
Number of pages6
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Issue number30
StatePublished - 15 Nov 2010


  • Hsp90 inhibitors
  • PF-04928473
  • PF-04929113
  • SNX-2112
  • SNX-5422


Dive into the research topics of 'Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry'. Together they form a unique fingerprint.

Cite this